A Preliminary Investigation into the Design of an Implantable Optical Blood Glucose Sensor

A. Trabelsi1,*, M. Boukadoum1, M. Siaj2

1Department of Computer Science, Université du Québec à Montréal, Montréal, H2X 3Y7, Canada
2Department of Chemistry, Université du Québec à Montréal, Montréal, H2X 3Y7, Canada

Abstract A preliminary investigation into the design of a near-infrared (NIR) optical bio-implant for accurate measurement of blood glucose level is reported. The use of an array of electrically pumped vertical-cavity surface-emitting laser (VCSEL) diodes at specific wavelengths for high-power narrow single-frequency emission leads to a high signal-to-noise ratio in the measured NIR absorption spectrum while maximizing the sensor’s sensitivity to small absorption changes. The emission wavelengths lie within the combination and first-overtone spectral bands known to be dominated by glucose absorption information. A Quantum well infrared (QWI) photodiode transducer senses the received optical power after passing through the blood sample, followed by an artificial neural network (ANN) for the measurement of glucose in a whole blood matrix. For an independent test set made with fresh bovine blood, the optimal ANN topology for processing the two selected spectral bands yielded a standard error of prediction of 0.42 mM (i.e., 7.56 mg/dl) over the glucose level range of 4–20 mM. The empirical results obtained with a prototype mounted on PCB for blood glucose monitoring are closely correlated with the absorption spectra collected on a Vertex 70 Bruker spectrometer.

Keywords NIR Spectroscopy, Blood Glucose Level, VCSEL, Artificial Neural Network, Optical Bio-Implant

1. Introduction

Diabetic patients need to monitor their blood glucose levels several times a day to prevent chronic complications related to the disease. Currently used methods for self-monitoring of blood glucose are invasive, uncomfortable, and usually require frequent finger pricking for withdrawing a drop of blood. Continuous blood glucose monitoring can lead to substantial improvements in blood glucose control. For this purpose, optical methods (i.e., NIR spectroscopy, polarimetry, Raman spectroscopy) for prediction of blood glucose levels may be an advantageous alternative to current biochemical-reaction and conductivity-based techniques. Their desirable features include a painless measurement process and the reduction of discomfort from repeated finger-stick readings.

Over the last decade, extensive efforts have been made both in academia and industry to develop optical blood glucose sensors that can perform continuous blood glucose measurements. An implantable optical blood glucose sensor based on NIR absorption spectroscopy was presented in [1]. In this work, the collected absorption spectra were analysed using two multivariate techniques, namely, Partial Least Squares (PLS) and Multiple Linear Regression (MLR).

In [2], the authors have proposed an optical sensing system based on a standard CMOS technology and absorption spectroscopy. In experiments using 430 nm and 650 nm light wavelengths, they showed that the detection limits of the suggested optical bio-sensor for glucose, H2O2, and histamine levels were at least one order of magnitude better that those of reported CMOS bio-sensors. In [3], a single 2.3 µm VCSEL structure was used to show the viability of glucose sensing in aqueous solutions, by using absorption spectroscopy and a PLS algorithm. A quantitative determination of glucose levels in whole blood samples using Fourier-transform infrared (FTIR) transmission spectroscopy was presented in [4]. The authors have found that the glucose level was proportional to the difference between the second derivative spectral values at two specific wave numbers (i.e., 1082 cm−1 and 1093 cm−1), suggesting that these two particular wavelengths can be used for direct determination of glucose levels in blood.

This paper focuses on the preliminary design guidelines of a novel NIR optical bio-implant for accurate measurement of blood glucose level. To improve the accuracy of the blood glucose predictions, a high signal-to-noise ratio (SNR) in the measured NIR absorption spectrum is required. The use of a VCSEL structure that provides high-power narrow single-frequency emission can fully meet this requirement. To maximize the sensor’s sensitivity to small absorption changes, an array of electrically pumped VCSELs emitting light at specific wavelengths will be used. The emission wavelengths fall within the combination (5000–4000 cm−1)
and first-overtone (6500−5500 cm−1) spectral bands known to enclose glucose-specific absorption features. A QWI photodiode transducer operating in the 1.2−2.5 µm range is required for optical power detection. A front-end transimpedance amplifier (TIA) is needed for the photodiode (PD) current. Readings will be transmitted via RF (radio-frequency) telemetry to an ANN-based model for the measurement of glucose level prior to be displayed on a display unit.

The paper is structured as follows. The next section presents the preliminary design guidelines of the optical blood glucose sensor implant in a conceptual fashion, giving an overview of the major sensor processing functions. Section 3 discusses the development of the ANN-based glucose calibration model and provides the empirical results with a prototype mounted on PCB for blood glucose monitoring. Conclusions are given in Section 4.

2. Implantable Blood Glucose Sensor

This section discusses preliminary design guidelines for an optical blood glucose sensor, giving an outline of the main anticipated sensor processing functions. Figure 1 illustrates the building block of the proposed implantable sensor. It consists of a pill-sized implant placed under the skin and an external RF reader and display module for the measured blood glucose level. The implant comprises an array of 6 VCSEL structures current-biased using a light-emitting diode (LED) drive controller, a QWI photodiode transducer, an analog front-end TIA for the PD current, and a CDMA (Code Division Multiple Access) subsystem for noise filtering. Digital-to-analog and analog-to-digital converters interface the CDMA subsystem to the LED drive controller and the TIA, respectively. An ANN-based model for blood glucose predictions is embedded within the RF reader.

2.1. Light Source

Development of semiconductor light-emitting devices is critical to optical blood glucose sensing using near-infrared absorption spectroscopy. Since glucose absorption spectrum has many features in the combination (2−2.5 µm) and first-overtone (1.54−1.82 µm) spectral bands, sample devices that could emit high-power narrow single-frequency light within these two wavelength ranges are required. Fortunately, InP-based VCSEL structures that could efficiently meet those requirements have recently been developed and shown to have stable emission spectra over a fairly broad wavelength range[5]. In our study, the VCSEL devices will be electrically pumped at wavelengths centered at 1.54, 1.67, 1.73, 2.10, 2.27 and 2.32 µm, respectively; where glucose has specific absorption features and water has relatively higher transmittance. The VCSEL devices are used in a round-robin sequence, from the one emitting at the shortest wavelength to the one emitting at the largest wavelength, until all devices are used.

2.2. Front-end TIA

Being the first active building block in the optical biosensor, the analog front-end TIA needed to resolve the value of the incoming signal from the sensor, has been a challenge to the sensor designer. Although a number of TIA’s topologies were reported in the literature[6-8], with varying degrees of success, the front-end still imposes unexpected constraints on photodiode use. For instance, the weak output current levels produced by the photodiode require large-area diodes and high-valued gain resistors. These requirements impose a trade-off between spectral response (gain and bandwidth), sensitivity (lower power level for a given signal-to-noise ratio), and overall temporal response (speed). As a result, successful compromises require careful design planning and impose variations on the basic PD front-end TIA[9].

![Figure 1. Building block of the implantable optical blood glucose sensor](Image)

The most commonly used CMOS front-end TIAs for optical sensing are the current-mode[6] and shunt-feedback[7] topologies. Both configurations strive to improve bandwidth by exhibiting low input impedance, thereby isolating the PD’s capacitance from the signal swing. Typically, the current-mode TIA uses wideband diode-connected topologies, such as the current mirror, for the input stage to sustain small input impedance and high bandwidth[8]. The basic current mirror circuit has very low input impedance, roughly equal to 1/gm (the small-signal transconductance of the input transistor), and its output current can readily be converted to voltage by means of a resistive load. The shunt-feedback topology uses a voltage amplifier with a feedback network and has the potential of lower overall input referred noise by optimizing the transistor sizes and aspect ratios in the amplifier’s input stage. Its input impedance at DC is then reduced to about Rf/Ad, where Rf is the transimpedance gain and Ad the open-loop gain of the voltage amplifier.

The current mode topology is attractive for wide bandwidth TIA design since stability is not an issue. However, the overall input-referred noise current of the current mode TIA is usually higher than that of the shunt-feedback topology for
a given bandwidth, resulting in a lower sensitivity of the front-end TIA. Due to its superior noise performance in this respect, the shunt-feedback topology is the starting circuit used in this work.

2.3. CDMA Subsystem

The CDMA subsystem is composed of a transmitter and receiver pair and used as an optical noise filter. This feature is original when considering that CDMA coding is mainly used as a communication channel access method. Moreover, it was shown by the authors in an earlier work[10] that using CDMA coding to drive the light source yields better noise immunity of the optoelectronic front-end than using the more common FDMA-oriented synchronous modulation approach. However, its bandwidth spreading mechanism and use of binary sequences to modulate the source signal complicate the design of the TIA. In this work, the CDMA transmitter will be used to modulate a constant bias signal by spreading its spectrum with 6 Gold pseudo-random sequences before applying it to the light emitting devices in a round-robin sequence, as described above. At the CDMA receiver, the opposite operations from the ones performed at the transmitter will take place.

2.4. Photodiode Transducer

InGaAs quantum structures grown on InP substrate for near-infrared photodetection were extensively investigated and commercialized in the last decade. Quantum well infrared photodiodes with sensitive wavelength as long as 2.6 µm were manufactured by numerous companies[11]. The optical composite signals after passing through the blood sample are detected by the QWI photodiode transducer which acts as a receiver and converts each optical signal into electric current that is then converted to a voltage by the TIA. Each analog voltage signal is then converted to its digital equivalent by the analog-to-digital converter, and CDMA-demodulated prior to be processed by an ANN-based model for forecasting blood glucose level.

2.5. RF Reader

The implant under the skin is powered by a current induced in a copper coil by a handheld antenna connected to an external RF reader. Being passive, the implant receives its energy from the outside and is only powered briefly during measurements over short intervals for minimum power consumption. When the voltage across a storage capacitor reaches the circuit operating voltage, the implant powers up and starts collecting data, which is stored and subsequently processed. Then, it sends the corresponding readings to the RF reader. The whole measurement/transmission process is expected to last 2 seconds at a time. The RF reader controls the acquisition and processing of telemetry data and feeds the measurement results to a display unit. The operational frequency of the RF reader should determine the optimal size, shape and geometry for the antenna and the coil[12].

2.6. ANN-based Model

Due to the non-linear spectral relationship between the NIR blood absorbances and glucose levels, a nonlinear multivariate technique is required for quantitative analysis of blood. Numerous multivariate analysis techniques (i.e., PLS, PCR (Principal Component Regression), MLR, ANN) were suggested in the literature[13-15]. Among these approaches, ANN-based models, such as the multi-layer perceptron (MLP), were shown to produce better results, compared with linear regression methods (i.e., PLS), in terms of prediction capabilities of analyte concentrations. In our study, the development of the ANN-based glucose calibration model over the combination and first-overtone spectral bands is performed by generating a dataset from bovine blood samples as described in the following section.

3. Experimental Arrangement and Preliminary Results

3.1. Experimental Setup

40 ml of bovine blood were divided into eight aliquots, collected into 10 ml sodium heparin tubes to prevent coagulation and stored in a refrigerator at a 4°C until needed. The bovine blood solutions were prepared in the following fashion. A 5-mL aliquot of blood was kept for 30 min at room temperature (23°C). Then, a small sample of this warmed blood was analysed to determine the base glucose level using a Nova Biomedical STP CCX analyzer. Base glucose values for the eight aliquots of blood were in the range of 4–5 mM. For each data acquisition experiment, a part of the remaining blood from each aliquot was flushed through the sample cell by using a syringe (1-mL). The sample cell was a demountable liquid transmission cell (model SL-3 cell, Cristal Laboratories) with CaF2 windows and a 400 µL sample volume. After each data acquisition experiment, the sample cell was cleaned with 50-mL of de-ionized water in the reverse direction. A Vertex 70 Bruker spectrometer was used for spectral sensing in the combination (5000–4000 cm−1) and first-overtone (6500–5500 cm−1) spectral bands. The Bruker spectrometer was equipped with a KBr-broadband beam-splitter and a liquid nitrogen-cooled mercury-cadmium telluride (LN-MCT Narrow) detector.

Blood glucose levels (BGLs) within the 4-20 mM range were targeted in this study. After the collection of twenty single-beam spectra from one of the unaltered aliquots of blood, a fixed amount of dried solid glucose was added to one of the remaining aliquots of blood to produce another sample. As this altered blood sample flushed through the sample cell, twenty new single-beam spectra were then taken. This procedure was repeated until seven successive glucose additions were completed and their corresponding spectra were acquired. For the 8 aliquots of blood, a total of 160 single-beam spectra were collected. For all FTIR spectra, Fourier processing with Blackman-Harris 3-Term apo-
dization, Mertz phase correction, 4 cm\(^{-1}\) resolution, and a zero-filling factor of two was performed with the OPUS software available for the Bruker spectrometer.

3.2. Glucose Calibration Model

Figure 2 presents a series of single-beam spectra collected from blood samples with different BGLs. It can be seen from this figure that step increase in glucose level gave rise to higher light absorption (i.e., lower transmission of light) through the blood. The FTIR spectra were analysed in terms of their correlation with their respective BGLs, using the feed-forward back-propagation neural network (FFBNN), from the Matlab neural network toolbox. The latter was trained using the Trainlm function that updates weight and bias values according to Levenberg-Marquardt optimization. The maximum number of epochs, the performance goal, the minimum performance gradient and the initial learning rate value were set to 10\(^2\), 10\(^{-10}\), 10\(^{-10}\) and 10\(^{-3}\), respectively. The connection weights between neurons and layers were adjusted to minimize the mean squared error (MSE) between the computed and the desired output values (MSE = 0 if a true solution existed).

The collected spectra were randomly split into three datasets, i.e. 60% served to train the network, 20% for validation of how well the network generalized, and 20% provided an independent test of network generalization to new data. Each pattern of the training dataset consisted of 6 values corresponding to spectral measurements at 6493, 5988, 4762, 4405 and 4310 cm\(^{-1}\) wavenumbers (i.e., 1.54, 1.67, 1.73, 2.1, 2.27, 2.32 \(\mu\)m wavelengths, respectively). Example set of the input patterns are illustrated in Table 1. The target outputs were the measured BGLs. The optimal ANN topology consisted of 8 hidden neurons and one output neuron, with hyperbolic tangent sigmoid (tansig) transfer function for the hidden layer, and linear transfer function (i.e, purelin) for the output layer.

The classification performance of the network following 24 training epochs is depicted in Figure 3. The training stopped after 18 epochs. The result shown in this figure is reasonable, since the test and validation set errors have similar characteristics, and it does not appear that any significant change overfitting (i.e., random error) occurred. To assess the prediction capabilities of the designed network, we carried out a linear regression between the feed-forward back-propagation neural network outputs and the corresponding targets, as shown in Figure 4. Considering the nonlinear dependency of the input data set, the network outputs appear to track the targets fairly well. A coefficient of determination (R\(^2\)) value of about 95% was obtained for all datasets, which is amongst the best results reported for predicting glucose levels in blood[1,2,4].

Table 1. Example set of input data patterns (multiple of 10\(^{-4}\))

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Wavelength ((\mu)m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.54 1.67 1.73 2.1 2.27 2.32</td>
</tr>
<tr>
<td>2</td>
<td>5.9 13.9 12.9 1.4 2.3 1.2</td>
</tr>
<tr>
<td>20</td>
<td>7.5 17.4 16.4 1.7 3 1.5</td>
</tr>
<tr>
<td>40</td>
<td>12 27.5 26.3 3 5.6 2.9</td>
</tr>
<tr>
<td>160</td>
<td>49.3 101 105. 10.5 22.4 11.3</td>
</tr>
</tbody>
</table>

Figure 2. Single-beam spectra from blood samples with different BGLs, from bottom to top: 4.73, 6.05, 9.87 and 12.91 mM, respectively, over the combination and the first overtone spectral bands.

3.3. Prototype Test Results

An experimental prototype, built from commercial off-
the-shelf components and mounted on PCB, was used as a starting circuit in this work to evaluate the potential of the implantable sensor in capturing data before transmitting it to the monitoring site. It was made up of an array of 6 infrared diodes current-biased using a LED drive controller, a photodiode transducer, and an analog front-end TIA for the PD current. Its simplified schematic is depicted in Figure 5. The infrared diodes (from MicroSensor, ir.microsensortech.com) emitted light at wavelengths centered at 1.54, 1.67, 1.73, 2.10, 2.27 and 2.32 µm, respectively. The photodiode PD24-05 from MicroSensor, with InGaAsSb/AlGaAsSb structures, was used to convert light into electric current. The basic shunt-feedback configuration was employed as an analog front-end TIA. It was made up of the OPA657U from Texas Instruments, in non-inverting mode with added voltage gain shunt-feedback configuration was employed as an analog front-end TIA. It was made up of the OPA657U from Texas Instruments, in non-inverting mode with added voltage gain shunt-feedback configuration was employed as an analog front-end TIA. It was made up of the OPA657U from Texas Instruments, in non-inverting mode with added voltage gain shunt-feedback configuration was employed as an analog front-end TIA. It was made up of the OPA657U from Texas Instruments, in non-inverting mode with added voltage gain. Its simplified schematic is depicted in Figure 5. The infrared diodes (from MicroSensor, ir.microsensortech.com) emitted light at wavelengths centered at 1.54, 1.67, 1.73, 2.10, 2.27 and 2.32 µm, respectively. The photodiode PD24-05 from MicroSensor, with InGaAsSb/AlGaAsSb structures, was used to convert light into electric current. The basic shunt-feedback configuration was employed as an analog front-end TIA. It was made up of the OPA657U from Texas Instruments, in non-inverting mode with added voltage gain and PD bootstrapping to remove the signal swing from the PD. The component values used in the measurements are summarized in Table 2.

![Schematic of the experimental prototype mounted on PCB](image)

**Figure 5.** Schematic of the experimental prototype mounted on PCB

<table>
<thead>
<tr>
<th>Component</th>
<th>$R_1$ (kΩ)</th>
<th>$R_2$ (kΩ)</th>
<th>$R_f$ (kΩ)</th>
<th>$R_1$ (kΩ)</th>
<th>$R_2$ (kΩ)</th>
<th>$C_1$ (pF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>22</td>
<td>2.2</td>
<td>22</td>
<td>1</td>
<td>2</td>
<td>8</td>
</tr>
</tbody>
</table>

The diodes were pulsed by a standard LED drive controller producing current pulses of approximately 0.5 ms width, up to 2 A output current and 50% duty cycle (as recommended by the manufacturer for maximum infrared lightning). The prototype was tested to measure the absorption characteristics of fresh bovine blood prepared as described above. BGLs within the 8-25 mM range were targeted. In this experiment, the sample cell was placed between the infrared diodes array and the photodiode, at equal distance (5 mm) on each side. The blood samples were analyzed to determine the corresponding glucose levels using the Nova Biomedical STP CCX analyzer.

Figure 6 shows the root-mean-squared (rms) output voltage of the front-end TIA as a function of BGL for the selected wavelengths (WLs). It can be inferred from this figure that step increase in glucose level led to lower rms output voltages (i.e., lower light transmission through the blood) as expected. For low BGLs (section I), the rms output voltage decreases linearly and sharply as the glucose level increases. For moderate BGLs (section II), a gradual decrease of the output voltage is observed. However, the output voltage remains almost constant at high BGLs (section III). This is essentially due to the high absorption of light through the blood being saturated by glucose. Better performance results are expected when silicon measurements will be performed.

![Graph showing RMS output voltage as a function of BGL for different wavelengths](image)

**Figure 6.** RMS output voltage as a function of BGL for different wavelengths

### 4. Conclusions

Preliminary design guidelines into the design of a blood glucose optical bio-implant based on NIR absorption spectroscopy for accurate measurement of blood glucose level are presented. The two important tasks performed by our optical bio-sensor during this preliminary phase of the project, were the collection of blood absorption spectra and the development of the ANN-based glucose calibration model over the combination and first-overtone spectral bands. These tasks were accomplished by generating a dataset from bovine blood samples. Although the obtained results are promising, the network performance could most likely be improved if input data patterns could be extended to include measurements of the energy, the first and second derivatives of the collected spectra. This research issue is currently being explored by the authors. The empirical results obtained with a prototype mounted on PCB for blood glucose monitoring were thus consistent with these preliminary results.

As was mentioned before, glucose exhibits several absorption bands in both the combination and the first-overtone spectral bands. Combination and overtone absorptions are mainly seen for C−H and O−H groups of glucose molecule [16]. In the NIR region, the absorption features of many blood components other than glucose (water, hemoglobin, proteins, etc.) are concentration dependent and are in similar or higher concentrations than glucose. For instance, the high concentration of water in blood with the relatively strong absorption of O−H groups result in large water absorbance bands. This gives rise to overlapping absorption features of glucose with those of other blood components. Therefore, measurement of blood glucose levels in several spectral bands rather than at one or few wavelengths is highly desired.

One of the main challenges for implantable biomedical devices is to develop adequate energy sources of reasonable size and long life. This imposes rigorous power requirements...
on an implant with an inductive RF power link, due to the low power efficiency of 1% or less associated with the size constraints of the implant. Fortunately, technologies that convert the body’s natural thermal energy and chemical gradients into electrical power are in development and would be a promising alternative to inductive power links for these devices[17]. Moreover, laying the ANN-based processing unit outside the patient’s body (i.e., on the RF Reader) will be expected to lead to lower power consumption.

Finally, efforts are currently under way to explore the resources needed for successful implementation of the optical sensor on silicon. We also plan to investigate the possible benefits in terms of improved system performance of an increase in the number of VCSELs within the array.

ACKNOWLEDGEMENTS

This work was financed by grants from FQRNT (Quebec), NSERC (Canada) and RESMIQ (Quebec). The authors wish to thank A. Mateescu (Université du Québec à Montréal) and C. Pellerin (Université de Montréal) for their contribution to this project and many fruitful discussions. We also thank J. F. Brodeur and M. Guay (Faculté de medicine vétérinaire de l’Université de Montréal) for assistance in bovine blood glucose sampling.

REFERENCES